journal article·2026-03Open access

Linker Manipulation with Beta 3 ‐Amino Acids Potentiates the Efficacy and Safety of PSMA Radiopharmaceuticals

Xin Gao, Jie Ma, Siqi Zhang, Zheng Chen, Jiang Wu, Dong Dai, Hongyi Huang, Qingshuang Lu, Shuo Jiang, Yuan Miao, Xueyao Chen, Feng Wang, Rui Wang, Lu Wang, Kuan Hu

Advanced Healthcare Materials· Volume 15· Issue 12

Abstract

ABSTRACT [ 177 Lu]Lu‐PSMA‐617 has achieved remarkable efficacy in the targeted radionuclide therapy (TRT) of metastatic castration‐resistant prostate cancer (mCRPC), yet challenges like salivary gland and renal toxicity remain. Linker manipulation is a well‐established strategy to enhance the efficacy and safety of prostate‐specific membrane antigen (PSMA)‐targeting radioligands. Notably, beta (β)‐amino acid moieties could improve in vivo pharmacological and pharmacokinetic profiles through modulating conformation, dynamics, and proteolytic susceptibility. Nevertheless, limited exploration of such moieties in PSMA‐targeting radioligands has been reported. Therefore, this study first developed a series of novel PSMA‐targeting radioligands through linker manipulation with beta 3 (β 3 )‐amino acids, aiming to potentiate the efficacy and safety. Preclinical evaluations showed that [ 68 Ga]Ga‐PSMA‐HK4 outperformed [ 68 Ga]Ga‐PSMA‐617 in tumor uptake, likely attributable to its optimized hydrophilicity and conformational flexibility. In a first‐in‐human trial involving 15 patients, [ 68 Ga]Ga‐PSMA‐HK4 demonstrated reduced salivary gland uptake (reductions of 35.8% and 48.1%) compared to [ 18 F]PSMA‐1007. It also exhibited superior diagnostic accuracy for equivocal lesions. Notably, the tumor uptake of [ 68 Ga]Ga‐PSMA‐HK4 in patients is overall higher than that of [ 68 Ga]Ga‐PSMA‐617. These findings underscore β 3 ‐amino acid linker manipulation with β 3 ‐amino acids as an effective strategy to enhance the performance of PSMA‐targeting radiopharmaceuticals, paving a new avenue for developing next‐generation agents and improving the precision of PSMA‐targeting TRT.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Prostate Cancer Treatment and Research · Radiopharmaceutical Chemistry and Applications · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

Center of Cyclotron and PET Radiopharmaceuticals Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research on Radiopharmaceuticals The First Affiliated Hospital of Jinan University Guangzhou China

Department of Urology the First Affiliated Hospital of Jinan University Guangzhou China

Department of Nuclear Medicine Nanjing First Hospital Nanjing Medical University Nanjing China

Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital & National Clinical Research Center for Cancer Tianjin Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer Tianjin China

Department of Nuclear Medicine Tianjin Cancer Hospital Airport Hospital National Clinical Research Center for Cancer Tianjin China

Funding

Beijing Nova Program · Fundamental Research Funds for the Central Universities · Peking Union Medical College · China Postdoctoral Science Foundation · Second Affiliated Hospital of Soochow University · Beijing Municipal Social Science Foundation · National Foundation for Medical Research and Innovation · Innovative Research Group Project of the National Natural Science Foundation of China

References (46)

Show source-provided references
1. 10.1038/s41392‐024‐02041‐610.1038/s41392‐024‐02041‐6 ↗
2. 10.1016/j.critrevonc.2024.10455610.1016/j.critrevonc.2024.104556 ↗
3. 10.1038/s41585‐022‐00670‐610.1038/s41585‐022‐00670‐6 ↗
4. 10.1021/acs.jmedchem.5c0208310.1021/acs.jmedchem.5c02083 ↗
5. 10.1021/cbmi.4c0007110.1021/cbmi.4c00071 ↗
6. 10.1016/j.addr.2022.11453810.1016/j.addr.2022.114538 ↗
7. 10.1056/NEJMoa210732210.1056/NEJMoa2107322 ↗
8. 10.2967/jnumed.119.23418710.2967/jnumed.119.234187 ↗
9. 10.1016/s1470‐2045(18)30198‐010.1016/s1470‐2045(18)30198‐0 ↗
10. 10.1016/j.apsb.2024.07.00610.1016/j.apsb.2024.07.006 ↗
11. 10.2967/jnumed.125.26949510.2967/jnumed.125.269495 ↗
12. 10.1007/s00259‐024‐06907‐310.1007/s00259‐024‐06907‐3 ↗
13. 10.3390/pharmaceutics1603034510.3390/pharmaceutics16030345 ↗
14. 10.1016/j.nucmedbio.2021.04.00310.1016/j.nucmedbio.2021.04.003 ↗
15. 10.2967/jnumed.123.26598610.2967/jnumed.123.265986 ↗
16. 10.1097/ju.000000000000368010.1097/ju.0000000000003680 ↗
17. 10.2174/092986732866621080409220010.2174/0929867328666210804092200 ↗
18. 10.3390/pharmaceutics1405109810.3390/pharmaceutics14051098 ↗
19. 10.1021/acs.jmedchem.5b0121010.1021/acs.jmedchem.5b01210 ↗
20. 10.2967/jnumed.114.14741310.2967/jnumed.114.147413 ↗
21. 10.1021/acs.molpharmaceut.2c0110110.1021/acs.molpharmaceut.2c01101 ↗
22. 10.1021/jm501089610.1021/jm5010896 ↗
23. 10.1039/b501173f10.1039/b501173f ↗
24. 10.1039/c4np00007b10.1039/c4np00007b ↗
25. 10.1002/cbdv.20049008710.1002/cbdv.200490087 ↗
26. 10.1385/1-59745-116-9:9510.1385/1-59745-116-9:95 ↗
27. 10.1038/s41557‐022‐01008‐w10.1038/s41557‐022‐01008‐w ↗
28. 10.1021/jacs.3c0987510.1021/jacs.3c09875 ↗
29. 10.1021/ja302428d10.1021/ja302428d ↗
30. 10.1021/jm980126v10.1021/jm980126v ↗
31. 10.1039/b807197g10.1039/b807197g ↗
32. 10.1039/c1cs15097a10.1039/c1cs15097a ↗
33. 10.1021/acs.jmedchem.9b0202210.1021/acs.jmedchem.9b02022 ↗
34. 10.1186/s41181‐024‐00237‐310.1186/s41181‐024‐00237‐3 ↗
35. 10.1038/s41585‐024‐00900‐z10.1038/s41585‐024‐00900‐z ↗
36. 10.1007/s00259‐020‐04945‐110.1007/s00259‐020‐04945‐1 ↗
37. 10.1039/c3cs60304k10.1039/c3cs60304k ↗
38. 10.1038/nrurol.2015.24210.1038/nrurol.2015.242 ↗
39. ProstaScint® Scan: Contemporary Use in Clinical Practice
40. 10.1007/s00259‐020‐05150‐w10.1007/s00259‐020‐05150‐w ↗
41. 10.1007/s00259‐017‐3780‐710.1007/s00259‐017‐3780‐7 ↗
42. 10.1016/j.tranon.2022.10144510.1016/j.tranon.2022.101445 ↗
43. 10.1038/s41391‐021‐00349‐w10.1038/s41391‐021‐00349‐w ↗
44. 10.1002/jmrs.22710.1002/jmrs.227 ↗
45. 10.1016/j.eururo.2020.11.01310.1016/j.eururo.2020.11.013 ↗
46. 10.1021/acsomega.4c1014210.1021/acsomega.4c10142 ↗